NEO
NeoGenomics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Buy
+22/100
Last price
16.51
▼ 2.63 (13.72%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
19.13
Day high
20.15
Day low
16.47
Volume
5.10M
Market cap
$2.12B
P/E (TTM)
—
52W range
7.07 – 20.15
Trailing performance
Returnvs SPY
1W
-11.90%
-13.8%
1M
-5.01%
-6.2%
3M
+15.94%
+11.4%
6M
+104.84%
+86.7%
YTD
+40.39%
+26.1%
1Y
+81.43%
+65.0%
3Y
+34.23%
-48.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on NEO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+203.49K
Net buying
Buy transactions
14
234.10K shares
Sell transactions
3
30.61K shares
Net transactions
+17
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
2.72M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 1, 26 | STONE WARREN President |
— | 17.56K | — | Direct |
| Aug 21, 26 | STONE WARREN President |
— | 28.11K | — | Direct |
| Aug 4, 26 | AUNAN GREGORY D Officer |
SELL | 20.00K | $321.40K | Direct |
| Jun 15, 26 | TETRAULT LYNN A. Director |
SELL | 5.31K | $58.91K | Direct |
| Jun 9, 26 | TETRAULT LYNN A. Director |
SELL | 5.31K | $59.92K | Direct |
| Jun 1, 26 | KELLY MICHAEL AARON Director |
— | 23.08K | — | Direct |
| Jun 1, 26 | GUNN NEIL Director |
— | 23.08K | — | Direct |
| Jun 1, 26 | GREEN MARJORIE C Director |
— | 22.96K | — | Direct |
| Jun 1, 26 | TETRAULT LYNN A. Director |
— | 23.08K | — | Direct |
| Jun 1, 26 | WILLIAMS FELICIA Director |
— | 23.08K | — | Direct |
| Jun 1, 26 | KANOVSKY STEPHEN MICHAEL Director |
— | 23.08K | — | Direct |
| Jun 1, 26 | KENNY JOHN P Director |
— | 5.89K | — | Direct |
| Jun 1, 26 | PEREZ DAVID BRIAN Director |
— | 23.08K | — | Direct |
| May 11, 26 | OLIVO ALICIA C General Counsel |
— | 3.94K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
HANNAH ALISON L. |
Director | 131.02K | Conversion of Exercise of derivative security |
HARRIS MELODY |
Officer | 109.75K | Conversion of Exercise of derivative security |
KANOVSKY STEPHEN MICHAEL |
Director | 75.42K | Conversion of Exercise of derivative security |
KELLY MICHAEL AARON |
Director | 72.09K | Conversion of Exercise of derivative security |
OLIVO ALICIA C |
General Counsel | 93.57K | Conversion of Exercise of derivative security |
SHERMAN JEFFREY SCOTT |
Chief Financial Officer | 220.01K | Conversion of Exercise of derivative security |
SMITH CHRISTOPHER MICHAEL |
Chief Executive Officer | 641.59K | Conversion of Exercise of derivative security |
STONE WARREN |
President | 191.73K | Conversion of Exercise of derivative security |
TETRAULT LYNN A. |
Director | 93.11K | Sale |
ZOOK ANTHONY P |
Chief Executive Officer | 152.01K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$2.12B
Enterprise value$2.42B
Revenue (TTM)$766.29M
Gross profit$336.53M
EBITDA$24.32M
Net income$-51.88M
EPS (TTM)$-0.39
Free cash flow$43.90M
Total cash$145.54M
Total debt$448.37M
Book value / share$6.14
Shares outstanding128.48M
Float117.02M
Short % of float15.35%
Dividend yield0.00%
Beta (5Y)1.78
Valuation & profitability ratios
Trailing P/E—
Forward P/E48.67
PEG ratio2.09
Price / sales—
Price / book2.69
EV / revenue3.16
EV / EBITDA99.62
Gross margin43.92%
Operating margin-4.84%
Profit margin-6.77%
Return on equity-6.33%
Return on assets-1.89%
Debt / equity57.06
Current ratio3.60
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $727.33M | $660.57M | $591.64M | $509.73M | +10.1% |
| Operating revenue | $727.33M | $660.57M | $591.64M | $509.73M | +10.1% |
| Cost of revenue | $413.04M | $370.47M | $347.04M | $321.83M | +11.5% |
| Gross profit | $314.29M | $290.10M | $244.60M | $187.90M | +8.3% |
| Research & development | $37.08M | $31.16M | $27.31M | $30.33M | +19.0% |
| Selling, general & admin | $331.65M | $310.49M | $279.96M | $277.91M | +6.8% |
| Total operating expense | $402.42M | $375.55M | $341.25M | $341.00M | +7.2% |
| Operating income | -$88.13M | -$85.45M | -$96.65M | -$153.11M | -3.1% |
| Net interest income | $5.32M | $11.81M | $9.99M | -$1.51M | -55.0% |
| Pre-tax income | -$110.27M | -$80.67M | -$97.10M | -$159.34M | -36.7% |
| Tax provision | -$2.24M | -$1.95M | -$9.13M | -$15.09M | -15.1% |
| Net income | -$108.03M | -$78.73M | -$87.97M | -$144.25M | -37.2% |
| Net income to common | -$108.03M | -$78.73M | -$87.97M | -$144.25M | -37.2% |
| Basic EPS | -0.84 | -0.62 | -0.70 | -1.16 | -35.5% |
| Diluted EPS | -0.84 | -0.62 | -0.70 | -1.16 | -35.5% |
| EBIT | -$106.52M | -$74.06M | -$90.19M | -$151.76M | -43.8% |
| EBITDA | -$38.69M | -$1.51M | -$17.61M | -$82.33M | -2,460.6% |
| Basic shares | 128.10M | 126.66M | 125.50M | 124.22M | +1.1% |
| Diluted shares | 128.10M | 126.66M | 125.50M | 124.22M | +1.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $159.62M | $367.01M | $342.49M | $263.18M | -56.5% |
| Cash & short-term investments | $159.62M | $386.84M | $415.20M | $437.99M | -58.7% |
| Accounts receivable | $159.24M | $150.54M | $131.23M | $119.71M | +5.8% |
| Inventory | $28.57M | $26.75M | $24.16M | $24.28M | +6.8% |
| Total current assets | $376.29M | $596.02M | $596.81M | $605.29M | -36.9% |
| Property, plant & equipment | $163.28M | $173.69M | $183.78M | $198.61M | -6.0% |
| Goodwill & intangibles | $810.87M | $862.45M | $895.89M | $931.03M | -6.0% |
| Total assets | $1.36B | $1.64B | $1.68B | $1.74B | -17.0% |
| Total current liabilities | $88.30M | $301.24M | $96.30M | $89.93M | -70.7% |
| Current debt | — | $200.78M | — | — | — |
| Long-term debt | $341.86M | $340.33M | $538.20M | $535.32M | +0.4% |
| Total debt | $409.46M | $605.33M | $611.68M | $610.93M | -32.4% |
| Total liabilities | $523.27M | $735.70M | $739.69M | $742.01M | -28.9% |
| Retained earnings | -$433.81M | -$325.78M | -$247.06M | -$159.09M | -33.2% |
| Shareholder equity | $836.56M | $902.34M | $941.54M | $998.02M | -7.3% |
| Working capital | $287.99M | $294.78M | $500.51M | $515.36M | -2.3% |
| Net tangible assets | $25.69M | $39.89M | $45.64M | $67.00M | -35.6% |
| Shares issued | 128.99M | 128.15M | 127.37M | 126.91M | +0.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$108.03M | -$78.73M | -$87.97M | -$144.25M | -37.2% |
| Depreciation & amortisation | $67.82M | $72.55M | $72.58M | $69.43M | -6.5% |
| Stock-based compensation | $41.32M | $33.41M | $24.63M | $24.67M | +23.7% |
| Change in working capital | -$32.09M | -$32.63M | -$25.49M | -$31.70M | +1.6% |
| Operating cash flow | $5.23M | $7.02M | -$1.95M | -$65.99M | -25.5% |
| Capital expenditure | -$27.01M | -$41.06M | -$28.75M | -$30.89M | +34.2% |
| Investing cash flow | -$12.34M | $12.86M | $76.71M | $517.00K | -196.0% |
| Financing cash flow | -$200.29M | $4.65M | $4.55M | $11.83M | -4,411.0% |
| Free cash flow | -$21.78M | -$34.04M | -$30.70M | -$96.88M | +36.0% |
| End cash position | $159.62M | $367.01M | $342.49M | $263.18M | -56.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $201.66M | $186.67M | $190.17M | $187.80M | $181.33M | +8.0% |
| Operating revenue | $201.66M | $186.67M | $190.17M | $187.80M | $181.33M | +8.0% |
| Cost of revenue | $109.78M | $105.81M | $106.83M | $107.35M | $104.07M | +3.8% |
| Gross profit | $91.88M | $80.86M | $83.34M | $80.45M | $77.26M | +13.6% |
| Research & development | $10.76M | $9.53M | $9.18M | $8.69M | $9.02M | +12.9% |
| Selling, general & admin | $90.89M | $89.57M | $53.26M | $91.68M | $95.82M | +1.5% |
| Total operating expense | $101.65M | $99.11M | $96.13M | $100.37M | $104.84M | +2.6% |
| Operating income | -$9.77M | -$18.24M | -$12.79M | -$19.93M | -$27.59M | +46.4% |
| Net interest income | $433.00K | $675.00K | $924.00K | $960.00K | $1.33M | -35.9% |
| Pre-tax income | $1.83M | -$17.58M | -$12.41M | -$26.39M | -$45.82M | +110.4% |
| Tax provision | -$412.00K | -$472.00K | -$2.52M | $740.00K | -$724.00K | +12.7% |
| Net income | $2.24M | -$17.11M | -$9.88M | -$27.13M | -$45.09M | +113.1% |
| Net income to common | $2.24M | -$17.11M | -$9.88M | -$27.13M | -$45.09M | +113.1% |
| Basic EPS | 0.02 | — | — | — | — | — |
| Diluted EPS | 0.02 | -0.13 | -0.08 | -0.21 | -0.35 | +115.4% |
| EBIT | $2.61M | -$16.98M | -$11.81M | -$25.79M | -$44.88M | +115.4% |
| EBITDA | $18.82M | -$567.00K | $4.59M | -$9.35M | -$27.62M | +3,418.7% |
| Basic shares | 129.63M | 129.17M | 128.65M | 128.41M | 127.95M | +0.4% |
| Diluted shares | 130.83M | 129.17M | 128.65M | 128.41M | 127.95M | +1.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $145.54M | $146.14M | $159.62M | $164.12M | $154.72M | — | -0.4% |
| Cash & short-term investments | $145.54M | $146.14M | $159.62M | $164.12M | $163.69M | — | -0.4% |
| Accounts receivable | $175.41M | $167.42M | $159.24M | $155.30M | $153.13M | — | +4.8% |
| Inventory | $27.14M | $29.84M | $28.57M | $28.46M | $34.17M | — | -9.0% |
| Total current assets | $381.48M | $373.68M | $376.29M | $382.46M | $392.55M | — | +2.1% |
| Property, plant & equipment | $166.20M | $160.36M | $163.28M | $165.62M | $168.33M | — | +3.6% |
| Goodwill & intangibles | $795.26M | $802.89M | $810.87M | $818.51M | $825.94M | — | -1.0% |
| Total assets | $1.35B | $1.35B | $1.36B | $1.37B | $1.39B | — | +0.4% |
| Total current liabilities | $105.88M | $84.59M | $88.30M | $97.87M | $100.12M | — | +25.2% |
| Current debt | — | — | — | — | — | $201.13M | — |
| Long-term debt | $374.24M | $342.24M | $341.86M | $341.48M | $341.10M | — | +9.4% |
| Total debt | $448.37M | $408.53M | $409.46M | $410.31M | $411.76M | — | +9.8% |
| Total liabilities | $566.51M | $517.77M | $523.27M | $536.49M | $539.91M | — | +9.4% |
| Retained earnings | -$448.67M | -$450.91M | -$433.81M | -$423.93M | -$396.80M | — | +0.5% |
| Shareholder equity | $785.73M | $828.76M | $836.56M | $838.29M | $854.04M | — | -5.2% |
| Working capital | $275.60M | $289.09M | $287.99M | $284.60M | $292.43M | — | -4.7% |
| Net tangible assets | -$9.53M | $25.87M | $25.69M | $19.78M | $28.10M | — | -136.8% |
| Shares issued | 127.92M | 129.65M | 128.99M | 128.89M | 128.68M | — | -1.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $2.24M | -$17.11M | -$9.88M | -$27.13M | -$45.09M | +113.1% |
| Depreciation & amortisation | $16.21M | $16.41M | $16.39M | $16.44M | $17.26M | -1.2% |
| Stock-based compensation | $8.22M | $9.64M | $8.04M | $10.31M | $12.21M | -14.7% |
| Change in working capital | $2.29M | -$19.20M | -$15.64M | -$226.00K | $14.01M | +111.9% |
| Operating cash flow | $19.96M | -$8.14M | $1.34M | $8.88M | $20.33M | +345.3% |
| Capital expenditure | -$8.22M | -$5.00M | -$7.87M | -$8.31M | -$6.32M | -64.4% |
| Investing cash flow | -$8.32M | -$5.00M | -$6.30M | -$277.00K | -$9.31M | -66.4% |
| Share buybacks | -$24.66M | -$338.00K | — | — | — | -7,196.4% |
| Financing cash flow | -$12.24M | -$338.00K | $431.00K | $765.00K | -$202.43M | -3,522.5% |
| Free cash flow | $11.74M | -$13.14M | -$6.53M | $570.00K | $14.01M | +189.4% |
| End cash position | $145.54M | $146.14M | $159.62M | $164.12M | $154.72M | -0.4% |
Options analytics
Put / call volume
0.09
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
10.00
-39.4% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
-6.2%
Calls bid over puts
Call volume
198
Contracts, this expiry
Put volume
17
Contracts, this expiry
Heaviest call OI
10.00
0 contracts
Heaviest put OI
16.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.03 | 0.05 | +48.6% |
| Mar 2026 | 0.00 | 0.01 | +800.9% |
| Dec 2025 | 0.04 | 0.06 | +50.0% |
| Sep 2025 | 0.02 | 0.03 | +25.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.05 | 11 | $206.81M | +10.1% |
| Next quarter | 0.07 | 11 | $210.20M | +10.5% |
| Current year | 0.18 | 11 | $804.69M | +10.6% |
| Next year | 0.34 | 11 | $884.84M | +10.0% |
Analyst targets & ownership
Mean target$21.15
High target$35.00
Low target$16.00
Implied upside28.14%
Analyst count10
ConsensusBUY
Strong buy / Buy2 / 7
Hold3
Sell / Strong sell0 / 0
Held by insiders2.11%
Held by institutions115.24%
Institutions holding373
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
18.55
-11.04% from price
SMA 20
18.62
-11.35% from price
SMA 50
17.38
-4.99% from price
SMA 100
14.73
+12.07% from price
SMA 200
12.39
+33.29% from price
EMA 12
18.37
-10.13% from price
EMA 26
18.16
-9.13% from price
EMA 50
17.22
-4.17% from price
RSI (14)
39.9
Neutral
MACD (12,26,9)
0.20
Hist -0.29
ATR (14)
1.08
6.52% of price
Realised vol 30D
64.0%
Annualised
Bollinger upper
20.37
20, 2σ
Bollinger lower
16.88
20, 2σ
50 / 200 cross
Golden
17.38 vs 12.39
Trend bias
Above 200
+33.29%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.95
Less volatile than market
Correlation to SPY
0.23
Largely independent
Realised vol 30D
64.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-45.6%
Peak to trough
Max drawdown 5Y
-89.7%
Peak to trough
ATR 14
1.08
6.52% of price
Beta (reported)
1.78
5Y monthly, from filing
Short interest
Shares short
16.71M
Prior 15.88M
Change vs prior
+5.2%
Shorts adding
% of float
15.35%
Elevated
% of shares out
13.01%
Against total outstanding
Days to cover
10.1
Crowded exit
Float
117.02M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 26 | StoneX | MAINTAINED | Buy | Buy |
| Oct 6, 26 | Needham | MAINTAINED | Buy | Buy |
| Oct 6, 26 | BTIG | UPGRADE | Neutral | Buy |
| Jul 29, 26 | Needham | MAINTAINED | Buy | Buy |
| Jul 24, 26 | Benchmark | MAINTAINED | Buy | Buy |
| Apr 29, 26 | Benchmark | UPGRADE | Hold | Buy |
| Apr 29, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Apr 29, 26 | Leerink Partners | UPGRADE | Market Perform | Outperform |
| Feb 24, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Feb 17, 26 | Needham | MAINTAINED | Buy | Buy |
| Jan 12, 26 | Needham | MAINTAINED | Buy | Buy |
| Sep 12, 25 | TD Cowen | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-05
Offering Registrations
S-8 · 2026-08-25
Corporate Changes & Voting Matters
8-K · 2026-08-11
Periodic Financial Reports
10-Q · 2026-07-28
Corporate Changes & Voting Matters
8-K/A · 2026-07-22
Corporate Changes & Voting Matters
8-K · 2026-07-20
Corporate Changes & Voting Matters
8-K · 2026-06-25
Corporate Changes & Voting Matters
8-K · 2026-06-22
Headlines
Why NeoGenomics (NEO) Stock Is Up Today
StockStory · 13h ago
Stryker, Neogenomics Announce CEO Transitions; Both Stocks Dive
Investor's Business Daily · 13h ago
NeoGenomics on 'More Solid Footing' With Strong Revenue Growth, Needham Says
MT Newswires · 15h ago
NeoGenomics Sinks 12% on CEO Succession Plan Despite Revenue Beat
TIKR · 17h ago
Did Strong Q3 Outlook and New CEO Plan Just Shift NeoGenomics' (NEO) Investment Narrative?
Simply Wall St. · 17h ago
Needham & Co Adjusts NeoGenomics Price Target to $22 From $19, Maintains Buy Rating
MT Newswires · 22h ago
BTIG Upgrades NeoGenomics to Buy From Neutral, Price Target is $28
MT Newswires · 23h ago
NeoGenomics stock falls on CEO transition announcement
Investing.com · 2d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.